Type 1 Diabetes
Conditions
Keywords
GLP-1, Type 1 diabetes, Glycemic control, Incretin hormone
Brief summary
The purpose of this study is to investigate whether secretion of incretin hormones is intact and to what extent endogenous as well as exogenous GLP-1 controls postprandial glucose excursions in patients with type-1 diabetes mellitus.
Detailed description
GLP-1 and GIP are incretin hormones secreted from specific endocrine celles in the gut. Stimulus for secretion is prescence of carbohydrates, fat and protein in the gut. The incretin hormones controls postprandial glucose excursions through stimulation of insulinsecretion as well as inhibition of glucagon and gastric emptying.The effects of GLP-1 on insulin secretion and glucagon inhibition are glucose dependent and the risc of hypoglycemia is therefore negligible when the hormone is administered in supra physiological concentrations.Furthermore, some animal studies suggest that GLP-1 has a trofic effect on the betacells and the hormone has been shown to replenish intracellular stores of insulin. Because the main bloodglucose lowering effect of GLP-1 has been thought to be due to increased insulin secretion, analouges of the hormone has been developed for the treatment of type-2 diabetes. So far, relatively little is known about the effect of GLP-1 in type-1 diabetes.It possible, that GLP-1 in combination with insulin (possibly mainly through its effect on glucagon inhibition and gastric emptying) could reduce the need for exogenous insulin with a concomitant reduced risc of hypoglycemia. Without compromising the target glucemic control. This study focuses of the postprandial bloodglucose lowering effects of endogenous as well as exogenous GLP-1 in patients with type-1 diabetes according to residual betacell function and glycemic control.Furthermore, the endogenous secretion of incretin hormones in patients with type-1 diabetes mellitus will be compared to that of matched normal controls.
Interventions
None listed
Sponsors
Hvidovre University Hospital
Eligibility
Sex/Gender
ALL
Age
18 Years to 60 Years
Healthy volunteers
Yes
Inclusion criteria
* type-1 diabetes mellitus * diagnosis between 5-40 years. * age 18-60 year * normal weight at time of diagnosis * insulintreatment from diagnosis * HbA1c \< 7.6 %
Exclusion criteria
* diabetic complications * disease other than type-1 diabetes
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| blood glucose | 4 hours |
Secondary
| Measure | Time frame |
|---|---|
| GLP-1 and GIP response during a meal | 4 hours |
| betacell function (incremental area under the c-peptide concentration curve) | 4 hours |
| alfa cell function (plasma glucagon) | 4 hours |
| gastric emptying | 4 hours |
Countries
Denmark
Outcome results
None listed